258 related articles for article (PubMed ID: 25085000)
1. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
Idorn M; Køllgaard T; Kongsted P; Sengeløv L; Thor Straten P
Cancer Immunol Immunother; 2014 Nov; 63(11):1177-87. PubMed ID: 25085000
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy.
Pal S; Nandi M; Dey D; Chakraborty BC; Shil A; Ghosh S; Banerjee S; Santra A; Ahammed SKM; Chowdhury A; Datta S
Aliment Pharmacol Ther; 2019 May; 49(10):1346-1359. PubMed ID: 30982998
[TBL] [Abstract][Full Text] [Related]
4. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
5. Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets.
Tomić S; Joksimović B; Bekić M; Vasiljević M; Milanović M; Čolić M; Vučević D
Front Immunol; 2019; 10():475. PubMed ID: 30936876
[TBL] [Abstract][Full Text] [Related]
6. Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.
Grützner EM; Hoffmann T; Wolf E; Gersbacher E; Neizert A; Stirner R; Pauli R; Ulmer A; Brust J; Bogner JR; Jaeger H; Draenert R
Front Immunol; 2018; 9():811. PubMed ID: 29760693
[TBL] [Abstract][Full Text] [Related]
7. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Hoechst B; Ormandy LA; Ballmaier M; Lehner F; Krüger C; Manns MP; Greten TF; Korangy F
Gastroenterology; 2008 Jul; 135(1):234-43. PubMed ID: 18485901
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Van Gele M; van Geel N; Brochez L
J Transl Med; 2015 Jan; 13():9. PubMed ID: 25592374
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
[TBL] [Abstract][Full Text] [Related]
10. Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients.
Napolitano M; D'Alterio C; Cardone E; Trotta AM; Pecori B; Rega D; Pace U; Scala D; Scognamiglio G; Tatangelo F; Cacciapuoti C; Pacelli R; Delrio P; Scala S
Oncotarget; 2015 Apr; 6(10):8261-70. PubMed ID: 25823653
[TBL] [Abstract][Full Text] [Related]
11. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
[TBL] [Abstract][Full Text] [Related]
12. Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells.
Hock BD; Mackenzie KA; Cross NB; Taylor KG; Currie MJ; Robinson BA; Simcock JW; McKenzie JL
Nephrol Dial Transplant; 2012 Jan; 27(1):402-10. PubMed ID: 21617199
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
[TBL] [Abstract][Full Text] [Related]
14. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease.
Kalathil SG; Lugade AA; Pradhan V; Miller A; Parameswaran GI; Sethi S; Thanavala Y
Am J Respir Crit Care Med; 2014 Jul; 190(1):40-50. PubMed ID: 24825462
[TBL] [Abstract][Full Text] [Related]
15. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion.
Luan Y; Mosheir E; Menon MC; Wilson D; Woytovich C; Ochando J; Murphy B
Am J Transplant; 2013 Dec; 13(12):3123-31. PubMed ID: 24103111
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.
Duffy A; Zhao F; Haile L; Gamrekelashvili J; Fioravanti S; Ma C; Kapanadze T; Compton K; Figg WD; Greten TF
Cancer Immunol Immunother; 2013 Feb; 62(2):299-307. PubMed ID: 23011590
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Weide B; Martens A; Zelba H; Stutz C; Derhovanessian E; Di Giacomo AM; Maio M; Sucker A; Schilling B; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Mar; 20(6):1601-9. PubMed ID: 24323899
[TBL] [Abstract][Full Text] [Related]
19. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C; Cagnon L; Costa-Nunes CM; Baumgaertner P; Montandon N; Leyvraz L; Michielin O; Romano E; Speiser DE
Cancer Immunol Immunother; 2014 Mar; 63(3):247-57. PubMed ID: 24357148
[TBL] [Abstract][Full Text] [Related]
20. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.
Jitschin R; Braun M; Büttner M; Dettmer-Wilde K; Bricks J; Berger J; Eckart MJ; Krause SW; Oefner PJ; Le Blanc K; Mackensen A; Mougiakakos D
Blood; 2014 Jul; 124(5):750-60. PubMed ID: 24850760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
